Journal Watch · Advanced Drug Delivery Reviews · 2026
The predictive edge: modeling and simulation in drug product development.
We highlight their role in improving drug performance, manufacturability, stability, safety, and overall success from clinical development through commercialization.
TL;DR
We highlight their role in improving drug performance, manufacturability, stability, safety, and overall success from clinical development through commercialization.
Key findings
- Advances in artificial intelligence (AI) and machine learning (ML) are proving transformative, enabling rapid analysis of large datasets and the development of predictive models that enhance classification, prediction, and optimization capabilities across the drug product development process.
- This review provides an overview of the various in-silico predictive modeling and simulation techniques for drug product development, emphasizing the use of AI/ML, and their applications in drug delivery.
- We highlight their role in improving drug performance, manufacturability, stability, safety, and overall success from clinical development through commercialization.
What they did
In response to these challenges, in-silico predictive modeling and simulations are becoming indispensable tools for accelerating and de-risking the drug product development process. These computational methods use simulated and real-world data to guide decision-making across the entire development pipeline. Notably, these tools are now gaining widespread acceptance not only in discovery but also across the delivery and formulation stages of drug development.
Full abstract (original)
Background: It is well-known that drug development is challenging and a time- and resource-intensive endeavor. Historically, it has relied heavily on trial-and-error, empirical approaches that yield a low probability of success. Despite continuous efforts to improve efficiency across the development stages the overall success rate from clinical trial initiation to market approval remains low.
What they did: In response to these challenges, in-silico predictive modeling and simulations are becoming indispensable tools for accelerating and de-risking the drug product development process. These computational methods use simulated and real-world data to guide decision-making across the entire development pipeline. Notably, these tools are now gaining widespread acceptance not only in discovery but also across the delivery and formulation stages of drug development.
Results & conclusions: Advances in artificial intelligence (AI) and machine learning (ML) are proving transformative, enabling rapid analysis of large datasets and the development of predictive models that enhance classification, prediction, and optimization capabilities across the drug product development process. This review provides an overview of the various in-silico predictive modeling and simulation techniques for drug product development, emphasizing the use of AI/ML, and their applications in drug delivery. We highlight their role in improving drug performance, manufacturability, stability, safety, and overall success from clinical development through commercialization.
Abstract © the authors / Advanced Drug Delivery Reviews (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.addr.2026.115784 · PubMed 41592638.
Why it matters for pharma & biotech
- Directly relevant to teams in AI in drug discovery / diagnostics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: AI in drug discovery / diagnostics
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Advanced Drug Delivery Reviews study find?
We highlight their role in improving drug performance, manufacturability, stability, safety, and overall success from clinical development through commercialization.
What type of study is this?
It is a review / perspective, published in Advanced Drug Delivery Reviews in 2026. In response to these challenges, in-silico predictive modeling and simulations are becoming indispensable tools for accelerating and de-risking the drug product development process.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.addr.2026.115784. PubMed ID: 41592638. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/the-predictive-edge-modeling-and-simulation-in-drug-product-development-115784/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides